Can art change the life of an Alzheimer’s patient? That’s the hope of a pilot program starting Thursday at the Detroit Institute of Arts – the museum launching the program for those suffering from the early stages of Alzheimer’s and dementia.
A distance runner is on the journey of his life, traveling through Michigan on a cross-country trek to raise money for Alzheimer’s research.
A fundraiser luncheon is scheduled for Wednesday, Aug. 10 at Traverse City St. Francis High School to raise money for research into Alzheimer’s and Parkinson’s diseases at Central Michigan University. The star of the plate will be the star of the research involved — cherries.
Kalamazoo-based Metabolic Solutions Development Co. said Wednesday that it has received a $773,000 grant from the Alzheimer’s Drug Discovery Foundation to conduct a pilot Phase 2a trial of MSDC-0160, MSDC’s pioneer compound for the treatment of metabolic diseases associated with altered mitochondrial function.
Peter Falk, the stage and movie actor who became identified as the squinty, rumpled detective in “Columbo”, has died at 83.
Ann Arbor-based Adeona Pharmaceuticals Inc. (NYSE Amex: AEN) announced Thursday that it has expanded its pipeline of proprietary zinc-based therapies to include a planned Phase IIb clinical trial of patients suffering from amyotrophic lateral sclerosis also known as Lou Gehrig’s Disease.
Nanoparticles of the right dimensions and shape may be the key in combating the plaque that destroys neurons and leads to symptoms associated with Alzheimer’s disease, a new report shows. University of Michigan chemical engineering professor Nicholas Kotov says the nanotechnology means can attract and capture the longer fibrils that are known to form plaque related to neurodegenerative disorders.
Ann Arbor-based Adeona Pharmaceuticals Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that it has executed an agreement with TG United, Inc. of Brooksville, Florida, to provide commercial-scale manufacturing capabilities for reaZin.
Ann Arbor-based Adeona Pharmaceuticals Inc. late Thursday reported top-line results from its clinical study evaluating reaZin for the dietary management of Alzheimer’s disease and mild cognitive impairment.
Ann Arbor-based Adeona Pharmaceuticals Inc. said Thursday that it had an agreement for the sale of 1,688,782 shares of its common stock at $2.0725 per share to a new institutional investor in a registered direct offering for $3.5 million in gross proceeds